AU2013255256B2 - Oral formulation - Google Patents

Oral formulation Download PDF

Info

Publication number
AU2013255256B2
AU2013255256B2 AU2013255256A AU2013255256A AU2013255256B2 AU 2013255256 B2 AU2013255256 B2 AU 2013255256B2 AU 2013255256 A AU2013255256 A AU 2013255256A AU 2013255256 A AU2013255256 A AU 2013255256A AU 2013255256 B2 AU2013255256 B2 AU 2013255256B2
Authority
AU
Australia
Prior art keywords
oral formulation
present
hydrochloride
maltodextrin
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013255256A
Other languages
English (en)
Other versions
AU2013255256A2 (en
AU2013255256A1 (en
Inventor
Taro Iwamoto
Nobuyuki Kurahashi
Yoshikazu Oka
Chikako TAKEDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU2013255256A1 publication Critical patent/AU2013255256A1/en
Publication of AU2013255256A2 publication Critical patent/AU2013255256A2/en
Application granted granted Critical
Publication of AU2013255256B2 publication Critical patent/AU2013255256B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
AU2013255256A 2012-04-30 2013-04-30 Oral formulation Ceased AU2013255256B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261640474P 2012-04-30 2012-04-30
US61/640,474 2012-04-30
US201361783163P 2013-03-14 2013-03-14
US61/783,163 2013-03-14
PCT/JP2013/062985 WO2013165021A1 (en) 2012-04-30 2013-04-30 Oral formulation

Publications (3)

Publication Number Publication Date
AU2013255256A1 AU2013255256A1 (en) 2014-10-30
AU2013255256A2 AU2013255256A2 (en) 2014-11-13
AU2013255256B2 true AU2013255256B2 (en) 2017-09-07

Family

ID=48483123

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013255256A Ceased AU2013255256B2 (en) 2012-04-30 2013-04-30 Oral formulation

Country Status (21)

Country Link
US (3) US20150126521A1 (cg-RX-API-DMAC7.html)
EP (1) EP2844232A1 (cg-RX-API-DMAC7.html)
JP (1) JP6360795B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150003898A (cg-RX-API-DMAC7.html)
CN (1) CN104271120A (cg-RX-API-DMAC7.html)
AR (1) AR091349A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013255256B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014026879A2 (cg-RX-API-DMAC7.html)
CA (1) CA2872004A1 (cg-RX-API-DMAC7.html)
CO (1) CO7151505A2 (cg-RX-API-DMAC7.html)
EA (1) EA026187B1 (cg-RX-API-DMAC7.html)
HK (1) HK1207290A1 (cg-RX-API-DMAC7.html)
IL (1) IL235111A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN09091A (cg-RX-API-DMAC7.html)
MX (1) MX2014013155A (cg-RX-API-DMAC7.html)
NZ (1) NZ630029A (cg-RX-API-DMAC7.html)
PH (1) PH12014502323A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201406261QA (cg-RX-API-DMAC7.html)
TW (1) TWI594765B (cg-RX-API-DMAC7.html)
WO (1) WO2013165021A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408114B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
US11654108B1 (en) 2022-05-02 2023-05-23 Medicated Chews, Llc Sennoside medicated chews

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002001962A2 (en) * 2000-06-30 2002-01-10 Biovail Technologies Ltd. A positive hydration method of preparing confectionery and the resulting product
US20080248102A1 (en) * 2007-04-05 2008-10-09 University Of Kansas Rapidly Dissolving Pharmaceutical Compositions Comprising Pullulan
WO2012046066A1 (en) * 2010-10-06 2012-04-12 Probio Asa Sour gelled emulsions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ970300A0 (en) * 2000-08-29 2000-09-21 Massa Nominees Pty Ltd Advanced wireless network
FR2822644B1 (fr) * 2001-03-30 2005-03-11 Roquette Freres Confiserie sans sucre
JP2004099558A (ja) * 2002-09-11 2004-04-02 Medorekkusu:Kk 医薬用ゼリー組成物
JP4547994B2 (ja) * 2004-06-02 2010-09-22 救急薬品工業株式会社 塊状物質含有積層フィルム状の可食性口腔内投与剤の製造方法および塊状物質含有積層フィルム状の可食性口腔内投与剤
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
WO2008050847A1 (en) * 2006-10-25 2008-05-02 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation prevented from caking
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
WO2010116385A2 (en) * 2009-04-08 2010-10-14 Rubicon Research Private Limited Pharmaceutical compositions for alleviating unpleasant taste
KR101074271B1 (ko) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
US20110139164A1 (en) * 2009-12-15 2011-06-16 R. J. Reynolds Tobacco Company Tobacco Product And Method For Manufacture
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
JP5611672B2 (ja) * 2010-05-28 2014-10-22 ゼリア新薬工業株式会社 経口ゼリー剤
AR082494A1 (es) * 2010-08-24 2012-12-12 Otsuka Pharma Co Ltd Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de silicona
WO2014104989A1 (en) * 2011-12-27 2014-07-03 Mahmut Bilgic Pharmaceutical compositions comprising aripiprazole

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002001962A2 (en) * 2000-06-30 2002-01-10 Biovail Technologies Ltd. A positive hydration method of preparing confectionery and the resulting product
US20080248102A1 (en) * 2007-04-05 2008-10-09 University Of Kansas Rapidly Dissolving Pharmaceutical Compositions Comprising Pullulan
WO2012046066A1 (en) * 2010-10-06 2012-04-12 Probio Asa Sour gelled emulsions

Also Published As

Publication number Publication date
IL235111A0 (en) 2014-12-31
IN2014DN09091A (cg-RX-API-DMAC7.html) 2015-05-22
CO7151505A2 (es) 2014-12-29
ZA201408114B (en) 2016-08-31
CA2872004A1 (en) 2013-11-07
PH12014502323A1 (en) 2015-01-12
JP2015515959A (ja) 2015-06-04
EP2844232A1 (en) 2015-03-11
AR091349A1 (es) 2015-01-28
HK1207290A1 (en) 2016-01-29
WO2013165021A1 (en) 2013-11-07
MX2014013155A (es) 2015-05-08
NZ630029A (en) 2016-05-27
SG10201608954UA (en) 2016-12-29
EA026187B1 (ru) 2017-03-31
TW201347773A (zh) 2013-12-01
SG11201406261QA (en) 2014-11-27
US20150126521A1 (en) 2015-05-07
JP6360795B2 (ja) 2018-07-18
KR20150003898A (ko) 2015-01-09
AU2013255256A2 (en) 2014-11-13
TWI594765B (zh) 2017-08-11
AU2013255256A1 (en) 2014-10-30
US20170202833A1 (en) 2017-07-20
CN104271120A (zh) 2015-01-07
EA201491995A1 (ru) 2015-02-27
US20180055840A1 (en) 2018-03-01
BR112014026879A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
JP6294479B2 (ja) 経口分散性フィルム
JP5674666B2 (ja) 崩壊性粒子組成物及び口腔内速崩壊錠
JP5674667B2 (ja) 崩壊性粒子組成物及び口腔内速崩壊錠
US20140335153A1 (en) Thin film with high load of active ingredient
CN110944640A (zh) 果胶胶粘组合物及其制造和使用方法
CN103025321A (zh) 快速溶解的药物释放系统
JP2015078182A (ja) 速崩壊性圧縮成型物及びその製法
WO2007119792A1 (ja) 乾式直打速崩壊性錠剤
US20210322306A1 (en) Oral dissolvable film with high load of polymeric binder
US20180055840A1 (en) Oral formulation
US11179331B1 (en) Oral soluble film containing sildenafil citrate
US11135217B2 (en) Manufacturing process of formulation having improved content uniformity
RU2582954C2 (ru) Фармацевтическая композиция в форме пероральной суспензии, которая содержит фракцию флавоноида и ксантановую камедь
JP5070669B2 (ja) 防腐性を向上した経口用ゲル製剤
JP6503626B2 (ja) 医薬組成物
UA113646C2 (xx) Пероральний препарат
MD4081187T2 (ro) Compoziție lichidă care conţine ibuprofen și fenilefrină
JP2012188383A (ja) ドネペジル塩酸塩の内用液剤
ES2565653T3 (es) Uso de betanecol para tratamiento de xerostomía
TW201306876A (zh) 乾粉漿組合物
JP2020203841A (ja) 服用直前に水を加えてゲル化させる固形剤
EA044204B1 (ru) Офтальмологический состав хлорпрокаина для местного применения
JP2019019060A (ja) 液体医薬組成物及び医薬品

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 17 OCT 2014

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired